Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Yuki Orikawa"'
Autor:
Takayuki Horii, Yuki Orikawa, Yuta Ohira, Runa Eta, Nobuyoshi Kobayashi, Takanori Sato, Takeshi Watanabe, Takao Tanaka
Publikováno v:
Cancer Cell International, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract The tumor microenvironment is one of the most important factors determining the efficacy of cancer immunotherapy. In particular, variability in efficacy has been linked to whether tumors are hot or cold, with hot tumors exhibiting greater T
Externí odkaz:
https://doaj.org/article/32e060b38010476894e83daa483fe01b
Autor:
Takayuki Horii, Yuki Orikawa, Yuta Ohira, Runa Eta, Uiko Tominaga, Takanori Sato, Takao Tanaka
Publikováno v:
Journal of Immunology Research, Vol 2022 (2022)
Background. Z-100 is a hot-water extract of the human-type Mycobacterium tuberculosis strain Aoyama B. While Z-100’s macrophage-mediated immunomodulatory effects have been reported, the mechanistic details have not been fully clarified. Here, we st
Externí odkaz:
https://doaj.org/article/99b69d2486094f4d9d1ed31f14ddd269
Autor:
Runa Eta, Takayuki Horii, Yuta Ohira, Yuki Orikawa, Nobuyoshi Kobayashi, Yuko Hori, Masahiro Okamoto, Takao Tanaka, Koji Yoshinaga, Kokichi Katsunuma, Mineo Takei, Koichi Seto
Publikováno v:
Biological and Pharmaceutical Bulletin. 37:642-647
Lymphatic metastasis is common in advanced-stage carcinoma and is associated with a poor prognosis. However, few effective treatments to inhibit it are available. Z-100 is an immunomodulatory extract of Mycobacterium tuberculosis strain Aoyama B that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e340546417860a9707aa82d95e73fde
https://doi.org/10.1248/bpb.b13-00927
https://doi.org/10.1248/bpb.b13-00927
Autor:
Koji Yoshinaga, Yuki Orikawa, Mineo Takei, Koichi Seto, Yuko Hori, Nobuyoshi Kobayashi, Tim Meyer, Hiroki Kato, Hiroki Hamano
Publikováno v:
Molecular Pain
Molecular Pain, Vol 6, Iss 1, p 72 (2010)
Molecular Pain, Vol 6, Iss 1, p 72 (2010)
Background: Z-360 is an orally active cholecystokinin-2 (CCK2)/gastrin receptor antagonist currently under development as a therapeutic drug for pancreatic cancer. It was previously reported that Z-360 treatment in combination with gemcitabine prolon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cccb2fec8efab3a7068b1be3b474640a
https://doi.org/10.1186/1744-8069-6-72
https://doi.org/10.1186/1744-8069-6-72
Autor:
Miki Okada-Iwabu, Ryo Nakayama, Yuki Orikawa, Toshimasa Yamauchi, Masato Iwabu, Kohjiro Ueki, Yoshihiro Shiomi, Koichiro Tanaka, Takashi Kadowaki, Yoshichika Yoshioka
A novel peroxisome proliferator-activated receptor (PPAR) modulator, Z-551, having both PPARα agonistic and PPARγ antagonistic activities, has been developed for the treatment of obesity and obesity-related metabolic disorders. We examined the effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44cf070b2e8c901f0e6f8a4aa014e6c2
https://europepmc.org/articles/PMC4505524/
https://europepmc.org/articles/PMC4505524/
Autor:
Takayuki, Horii, Koji, Yoshinaga, Nobuyoshi, Kobayashi, Koichi, Seto, Yuki, Orikawa, Masahiro, Okamoto, Runa, Eta, Yuta, Ohira, Kokichi, Katsunuma, Yuko, Hori, Takao, Tanaka, Mineo, Takei
Publikováno v:
Biologicalpharmaceutical bulletin. 37(4)
Lymphatic metastasis is common in advanced-stage carcinoma and is associated with a poor prognosis. However, few effective treatments to inhibit it are available. Z-100 is an immunomodulatory extract of Mycobacterium tuberculosis strain Aoyama B that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7dc42486c78dc2406c6874d95034aacc
https://pubmed.ncbi.nlm.nih.gov/24818259
https://pubmed.ncbi.nlm.nih.gov/24818259
Autor:
Yasushi Kuraishi, Koji Yoshinaga, Koichi Seto, Yuki Orikawa, Runa Eta, Tomoko Ozaki, Mineo Takei, Hiroki Hamano, Takayuki Horii, Kazuyoshi Yoshii, Yuko Hori, Yoshihiro Kawabata
Publikováno v:
Biologicalpharmaceutical bulletin. 33(2)
Z-360, a novel cholecystokinin(2) (CCK(2)) receptor antagonist, has been developed as a therapeutic drug for pancreatic cancer and showed pain relief action in phase Ib/IIa clinical trial. This study was attempted to elucidate the analgesic efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d6a0c06bf6577d800db35a6e6fe35e5
https://pubmed.ncbi.nlm.nih.gov/20118547
https://pubmed.ncbi.nlm.nih.gov/20118547
Autor:
Yuta Ohira, Yuki Orikawa, Takahiro Sasaki, Koichi Seto, Mineo Takei, Yoshihiro Shiomi, Nobuyoshi Kobayashi, Koichiro Tanaka, Kokichi Katsunuma, Makoto Yoshimura
Publikováno v:
Gastroenterology. 140:S-603
adults (13 weeks of age) (infant+/adult+) and 2) rats gavaged with vehicle only as infants and subsequent gavage with 108 cfu wild-type C. jejuni as adults (infant-/adult+). After inoculation with C. jejuni (as infants or adults), stool was collected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2da471902fbbe72465ea4689dac4471f
https://doi.org/10.1016/s0016-5085(11)62496-7
https://doi.org/10.1016/s0016-5085(11)62496-7
Autor:
Yoshihiro Shiomi1,2, Toshimasa Yamauchi1,3, Masato Iwabu1, Miki Okada-Iwabu1, Ryo Nakayama1, Yuki Orikawa2, Yoshichika Yoshioka4, Koichiro Tanaka2,5, Kohjiro Ueki1, Takashi Kadowaki1 kadowaki-3im@h.u-tokyo.ac.jp
Publikováno v:
Journal of Biological Chemistry. 6/5/2015, Vol. 290 Issue 23, p14567-14581. 15p.